Document:

<PAGE>
                                                                   EXHIBIT 10.12

                              EMPLOYMENT AGREEMENT

                                     BETWEEN

                                 AMEDISYS, INC.

                                       AND

                                   JOHN NUGENT

                                 October 1, 2001

<PAGE>

                              EMPLOYMENT AGREEMENT

               THIS EMPLOYMENT AGREEMENT ("Agreement") entered into as of the
1st day of October, 2001, and continuing for an indefinite duration, by and
between AMEDISYS, INC., a Delaware corporation (the "Company") and JOHN NUGENT
("NUGENT").

                                   RECITALS:

               A. The Company owns, manages and/or operates agencies and
facilities for the provision of home health care services (the "Business").

               B. NUGENT is employed by the Company as the Chief Development
Officer;

               NOW, THEREFORE, in consideration of the mutual promises and
covenants contained in this Agreement, the parties agree as follows:

               1. RECITATIONS. The above recitations are incorporated herein by
this reference.

               2. PERFORMANCE OF DUTIES. NUGENT shall perform such duties as are
usually performed by the Chief Development Officer of health care companies of a
business similar in size and scope as the Company and such other reasonable
additional duties as may be prescribed from time to time by the Company's Chief
Executive Officer which are reasonable and consistent with the expectations of
the Company and the Company's operations, taking into account NUGENT's expertise
and job responsibilities, including but not limited to, adherence to internal
compliance and governmental and regulatory rules, regulations and applicable
laws. NUGENT shall report directly to the Chief Executive Officer of the Company
or his designee.

                       2.1 Devotion of Time. NUGENT agrees to devote full time
and attention to the business and affairs of the Company to the extent necessary
to discharge the responsibilities assigned to NUGENT and to use reasonable best
efforts to perform faithfully and efficiently such responsibilities.

               3. TERMINATION OF EMPLOYMENT.

                       3.1 Termination of Employment by the Company for Cause.
The Company may terminate NUGENT's employment for Cause, as defined herein,
without any obligation of severance payments to NUGENT. Cause shall be defined
as follows:

                                (a) a material default or breach by NUGENT of
any of the provisions of this Agreement materially detrimental to the Company
which is not cured within thirty (30) days following written notice thereof;

                                (b) actions by NUGENT constituting fraud,
embezzlement or dishonesty which result in a conviction of a criminal offense
not overturned on appeal;

                                (c) intentionally furnishing materially false,
misleading, or omissive information to the Company's Chief Executive Officer,
Board of Directors or any committee of the Board of Directors, that is
materially detrimental to the Company;

                                (d) actions constituting a breach of the
confidentiality of the Business and/or trade secrets of the Company which is
materially detrimental to the Company; and

                                      -2-
<PAGE>

                                (e) willful failure to follow reasonable and
lawful directives of the Company's Chief Executive Officer or Board of
Directors, which are consistent with NUGENT's job responsibilities and
performance which is not cured within thirty (30) days following written notice
thereof.

                       3.2 Termination Without Cause. The Company shall have the
right to terminate NUGENT' employment without Cause, at any time and subject to
the sole discretion of the Company. In such event, NUGENT will cease to have any
power of his position as of the effective date of the termination.

                       3.3 Termination by NUGENT. NUGENT may terminate his
employment upon thirty (30) days written notice to the Company. Such notice
shall set forth in sufficient detail for the Company to understand the nature of
the facts underlying said termination.

                       3.4 Change of Control. Upon the occurrence of a "Change
of Control," if such occurs prior to NUGENT's receiving a notice of termination
by the Company for Cause, NUGENT shall be entitled to the Severance described
herein. "Change of Control" is defined as the following:

                                (a) The acquisition by any person, entity or
"group" within the meaning of Section 13(d) or 14(d) of the Securities Exchange
Act of 1934 (the "Exchange Act") of beneficial ownership (within the meaning of
Rule 13d-3 promulgated under the Exchange Act) of fifty-one (51%) percent or
more of either the then outstanding shares of the Company's common stock or the
combined voting power of the Company's then outstanding voting securities
entitled to vote generally in the election of directors; provided however,
purchase by underwriters in a firm commitment public offering of the Company's
securities or any securities purchased for investment only by professional
investors shall not constitute a Change of Control; and

                                (b) The individuals who serve on the Company's
Board of Directors as of the effective date of this Agreement (the "Incumbent
Board") cease for any reason to constitute at least a majority of the Board of
Directors of the Company; provided, however, any person who becomes a director
subsequent to the effective date of this Agreement, whose election or nomination
for election by the Company's shareholders was approved by a vote of at least a
majority of the directors then compiling the Incumbent Board, shall for purposes
of this Agreement be considered as if such person was a member of the Incumbent
Board.

               4. COMPENSATION.

                       4.1 Salary. Company shall pay to NUGENT a base salary at
the annual rate of $175,000 (the "Base Salary"). Notwithstanding anything herein
to the contrary, the Company shall have the sole discretion at any time and from
time to time to increase the Base Salary. Base Salary shall be payable in
installments consistent with the Company's normal payroll schedule, in effect
from time to time, subject to applicable withholding and other taxes.

                       4.2 Base Salary Increases. Commencing October 1, 2002,
NUGENT's Base Salary shall be automatically increased on February 1 of each year
during the term hereof by the greater of (i) six (6%) percent, or (ii)
$12,000.00. Notwithstanding anything herein to the contrary, the Chief Executive
Officer may grant a Base Salary Increase in excess of the amount stipulated to
within this Section 4.2.

                       4.3 Bonus. At the end of each fiscal year of employment,
the Company shall pay NUGENT a bonus up to $87,500, payable in terms which shall
be at the Company's discretion, and only if the Company attains or exceeds the
operating income (loss) as presented in the budget approved by the Company's
Board of Directors for that fiscal year, and if certain performance based
criteria which shall, from time to time, be determined by the Company and made
known to NUGENT are met. Notwithstanding anything herein to the contrary, the
Chief Executive Officer may pay a bonus in excess of the amount earned

                                      -3-
<PAGE>

pursuant to this Section 4.3. Any bonus payments due hereunder are subject to
set-off pursuant to that certain Loan Agreement by and between the Company and
Nugent of even date herewith.

                       4.4 Stock Options. Upon execution of this Agreement,
Nugent shall be granted options to purchase 25,000 shares of the Company's
common stock, said grant date to be October 1, 2001. On October 1, 2003, and on
October 1 of each following year during the term hereof, the Company shall cause
to be granted to NUGENT, pursuant to a stock option plan duly adopted by the
Company or otherwise, options to purchase such number of shares of the Company's
common stock equal to the greater of (i) seventy five one-hundredths (.75%)
percent of the number of shares of Company common stock issued by the Company
during the preceding fiscal year; or (ii) 12,500 shares. Notwithstanding
anything herein to the contrary, NUGENT shall not be entitled to the grant of
options during any time in which NUGENT is receiving severance payments from the
Company, as outlined below. Notwithstanding anything herein to the contrary, the
Chief Executive Officer may recommend that the Board of Directors of the Company
grant options in excess of the amount stipulated to in this Section 4.4.

                       4.5 Severance Compensation. Should NUGENT be terminated
without Cause, as defined herein, or should a Change of Control, as defined
herein, occur during NUGENT's employment with Company, NUGENT shall be entitled
to severance compensation in an amount equal to eighteen (18) months of NUGENT's
Base Salary at the time of such termination without cause or Change of Control,
payable at the discretion of the Company, but at a minimum, payable by the
Company via regularly scheduled payroll distributions until the entire severance
amount due NUGENT is paid in full. Severance compensation is subject to set-off
pursuant to that certain Loan Agreement by and between the Company and Nugent of
even date herewith.

                       4.6 Additional Benefits.

                                (a) Vacation. NUGENT shall be entitled to the
maximum amount of paid time off for Company employees stipulated by the Company
PTO policy during each calender year of his employment with the Company. In
addition, NUGENT shall be entitled to paid time off for the same holidays as
other employees of the Company as established by the Company's Board of
Directors.

                                (b) Reimbursement of Expenses. NUGENT is
authorized to incur reasonable traveling and other expenses in connection with
the Business and in performance of his duties under this Agreement. NUGENT shall
be reimbursed by the Company for all Business expenses which are reasonably
incurred by NUGENT. All reimbursable travel expenses shall be in accordance with
mutually agreeable and reasonable policy.

                                (c) Participation in Employee Benefit Plans.
NUGENT shall be entitled to participate, subject to eligibility and other terms
generally established by the Company's Board of Directors, in any employee
benefit plan (including but not limited to life insurance plans, long-and
short-term disability, stock option plans, group hospitalization, health, dental
care plans, (which health insurance plans shall also cover NUGENT's dependents)
profit sharing and pension, and other benefit plans), as may be adopted or
amended by the Company from time to time.

               5. REPRESENTATION BY NUGENT. NUGENT hereby represents to the
Company that he is physically and mentally capable of performing his duties
hereunder and he has no knowledge of present or past physical or mental
conditions which would cause him not to be able to perform his duties hereunder.

                                      -4-
<PAGE>

               6. CONFIDENTIALITY AND NON-DISCLOSURE OF INFORMATION.

                       6.1 Confidentiality. NUGENT shall not, during his
employment with the Company or any time thereafter, divulge, furnish or make
accessible to anyone, without the Company's prior written consent, any knowledge
or information with respect to any confidential or secret aspect of the Business
which if disclosed could reasonably be expected to have a material adverse
effect on the Business ("Confidential Information").

                       6.2 Ownership of Information. NUGENT recognizes that all
Confidential Information and copies or reproductions thereof, relating to the
Company's operations and activities made or received by NUGENT in the course of
his employment are the exclusive property of the Company, as the case may be,
and NUGENT holds and uses same as trustee for the Company and subject to the
Company's sole control and will deliver same to the Company at the termination
of his employment, or earlier if so requested by the Company in writing. All of
such Confidential Information, which if lost or used by NUGENT outside the scope
of his employment, could cause irreparable and continuing injury to the
Company's Business for which there may not be an adequate remedy at law. NUGENT
acknowledges that compliance with the provisions of this Section 6 is necessary
to protect the goodwill and other proprietary interests of the Company and is a
material condition of employment.

               7. RESTRICTIVE COVENANT. As an inducement to cause the Company to
enter into this Agreement, and in consideration of the Severance obligation of
Company herein, NUGENT covenants and agrees that during his employment and, for
a period of eighteen (18) months after he ceases to be employed by Company,
regardless of the manner or cause of termination:

                       7.1 Solicitation of Business. He will not initiate any
contact with, call upon, solicit Business from, sell or render services to any
client or patient of the Company or any Company affiliate, within any area which
the Company conducts business, a list of which is included in Schedule 7.1,
which is attached hereto and incorporated herein ("Restricted Area"), for or on
behalf of himself or any business, firm, proprietorship, corporation,
partnership, association, entity or venture primarily engaged in the business of
providing home health, alternate site infusion therapy or ambulatory surgery
services, which is a similar business as the Business ("Competing Business"),
and NUGENT shall not directly or indirectly aid or assist any other person, firm
or corporation to do any of the aforesaid acts.

                       7.2 Solicitation of Employees. He will not directly or
indirectly, as principal, agent, owner, partner, stockholder, officer, director,
employee, independent contractor or consultant of any competing Business, or in
any individual or representative capacity hire, solicit, directly or indirectly
cause others to hire, or solicit the employment of, any officer, sales person,
agent, or other employee of the Company or any Company affiliate, for the
purpose of causing said officer, sales person, agent or other person to
terminate employment with the Company or any Company affiliate and be employed
by such competing Business.

                       7.3 Employment. He will not accept or engage employment
with, or consult, contract or otherwise provide services to, any Competing
Business operating within the Restricted Area.

                       7.4 Material Violation. A proven material violation of
this Section 7 shall constitute a material and substantial breach of this
Agreement and shall result in the imposition of the Company's remedies contained
in Section 8 herein. NUGENT acknowledges and agrees that proof of such personal
solicitation by NUGENT of an employee shall constitute absolute and conclusive
evidence that NUGENT has substantially and materially breached the provisions of
this Agreement.

                       7.5 Other Employment. It is understood by and between the
parties that the foregoing covenants set forth in Sections 6 and 7 are essential
elements of this Agreement, and that but for

                                      -5-
<PAGE>

the Agreement of NUGENT to comply with such covenants, the Company would not
have entered into this Agreement. Such covenants by NUGENT shall be construed as
agreements independent of any other provision of this Agreement and the
existence of any claim or cause of action NUGENT may have against the Company
whether predicated on this Agreement or otherwise, shall not constitute a
defense to the enforcement by Company of these covenants.

                       7.6 Defaults and Deferred Compensation.

                                (a) NUGENT Breach. If NUGENT breaches any
requirement of Section 7 herein, in addition to any other remedy to which the
Company may be entitled, NUGENT shall return to the Company any Severance
already paid to NUGENT at the time of said breach, and all of NUGENT's rights to
receive any portion of his Severance not already paid to him shall terminate.
The right to receive unpaid Severance will not be reinstated notwithstanding any
cessation by NUGENT of his breach of Section 7.

                       7.7 Discontinued Operations. Notwithstanding anything in
this Section 7 to the contrary, this Section 7 shall not apply to any of the
Company's product or service divisions which at the time of NUGENT's employment
termination was considered by the Company to be a discontinued operation.

               8. REMEDIES. NUGENT hereby acknowledges, covenants and agrees
that in the event of a material default or breach under this Agreement, in
addition to any other remedy set forth herein:

                       8.1 Company may suffer irreparable and continuing damages
as a result of such breach and its remedy at law will be inadequate. NUGENT
agrees that in the event of a violation or breach of this Agreement, in addition
to any other remedies available to it, Company shall be entitled to an
injunction restraining any such default or any other appropriate decree of
specific performance, with the requirement to prove actual damages or to post
any bond or any other security and to any other equitable relief the court deems
proper; and

                       8.2 Any and all of Company's remedies described in this
Agreement shall not be exclusive and shall be in addition to any other remedies
which Company may have at law or in equity including, but not limited to, the
right to monetary damages.

               9. SEVERABILITY. The invalidity of any one or more of the words,
phrases, sentences, clauses, sections, subdivisions, or subparagraphs contained
in this Agreement shall not affect the enforceability of the remaining portions
of this Agreement or any part thereof, all of which are inserted conditionally
on their being legally valid.

               10. SUCCESSORS AND ASSIGNS.

                       10.1 Successors. This Agreement shall be binding upon the
parties hereto and their successors and assigns. For purposes of this Agreement,
the term "successor" of Company shall include any person or entity, whether
direct or indirect, whether by purchase, merger, consolidation, operation of
law, assignment, or otherwise acquires or controls: (i) all or substantially all
of the assets of Company (ii) fifty- one percent (51%) or more of the total
voting capital stock, and was not affiliated with or in common control of
Company as of the date of this Agreement; or (iii) any other Business
combination with or without the consent of Company's shareholders.

                       10.2 Assignment. This Agreement shall be non-assignable
by either Company or NUGENT without the written consent of the other party, it
being understood that the obligations and performance of this Agreement are
personal in nature.

                                      -6-
<PAGE>

               11. MISCELLANEOUS.

                       11.1 Amendment. No amendment, waiver or modification of
this Agreement or any provisions of this Agreement shall be valid unless in
writing and duly executed by both parties.

                       11.2 Binding Agreement. This Agreement shall be binding
upon and inure to the benefit of the parties and their respective heirs, legal
representatives, successors and assigns.

                       11.3 Waiver. Any waiver by any party of any breach of any
provision of this Agreement shall not be considered as or constitute a
continuing waiver or waiver of any other breach of any provision of this
Agreement.

                       11.4 Captions. Captions contained in this Agreement are
inserted only as a matter of convenience or for reference and in no way define,
limit, extend, or describe the scope of this Agreement or the intent of any
provisions of this Agreement.

                       11.5 Attorneys' Fees. In the event of any litigation
arising out of this Agreement the prevailing party shall be entitled to recover
from the other party its attorneys' fees and costs, including attorneys' fees
and costs incurred on appeal.

                       11.6 Prior Agreements. This Agreement supersedes and
replaces all prior agreements between the parties hereto dealing with the
subject matter hereof.

                       11.7 Governing Law. This Agreement shall be governed by
the laws of Louisiana.

                       11.8 Execution. It is the intention of the parties hereto
that this Agreement will not be valid and binding upon the parties hereto until
such time as this Agreement is executed by both parties in accordance herewith.

               IN WITNESS WHEREOF, the parties have executed this Agreement as
of the day and year first above written.

                                           AMEDISYS, INC.

                                           By:
                                              ---------------------------------
                                                    WILLIAM F. BORNE, CEO

                                           ------------------------------------
                                                        JOHN NUGENT

                                      -7-<PAGE>
                                                                   EXHIBIT 10.13

                                 LOAN AGREEMENT

         This Loan Agreement ("Loan Agreement") is made and entered into as of
this 1st day of October, 2001, by and among AMEDISYS, INC., a Delaware
corporation (the "Lender") and JOHN NUGENT, an individual of the full age of
majority (referred to herein as the "Borrower").

                                   WITNESSETH

         WHEREAS, the Borrower and the Lender have entered into that certain
Promissory Note dated as of even date herewith whereby the Lender agreed to loan
to the Borrower and the Borrower agreed to pay the Lender the principal sum not
to exceed ONE HUNDRED TWO THOUSAND AND 00/100 DOLLARS ($102,000.00) pursuant to
the terms and provisions specified herein (the "Note");

         WHEREAS, in order to induce the Lender to enter into this Loan
Agreement and as security for the performance of the Borrower's obligations
under the Note, the Borrower has agreed to grant to Lender a security interest
in certain Collateral (as defined below).

         NOW, THEREFORE, in order to secure performance of the Borrower's
obligations under the Note, and for other valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, it is agreed as follows:

         1. RECITALS. The recitals set forth above are hereby incorporated as
terms and provisions hereof.

         2. LOAN. The Lender hereby agrees to loan to the Borrower the principal
amount not to exceed ONE HUNDRED TWO THOUSAND AND 00/100 DOLLARS ($102,000.00),
payable as follows:

         a)       $4,200.00 per month commencing October 1, 2001 and continuing
                  payments on the 1st day of each month through July 1, 2002;
                  and

         b)       $5,000.00 per month commencing August 1, 2002 and continuing
                  payments on the 1st day of each month through July 1, 2003.

         3. INTEREST. The interest rate for outstanding loan balances shall be
SIX PERCENT (6%) per annum. Interest on the Note shall be computed on the basis
of a 360-day year and actual days elapsed.

         4. INSTALLMENTS. Interest and principal payments shall be made pursuant
to the terms of the Note.

         5. PAYMENT. Borrower shall pay Lender, in lawful money of the United
States of America to such account as may be specified by Lender from time to
time.

         6. PREPAYMENT. The Borrower shall have the right to prepay the
principal balance outstanding in whole or in part.

<PAGE>

         7. GRANT OF A SECURITY INTEREST. The Borrower hereby grants a security
interest to the Lender, and its successors and assigns, in, to and under the
following, which shall sometimes be collectively referred to herein as the
"Collateral";

                           (a) all monies due borrower as bonus payments
                           pursuant to that certain Employment Agreement by and
                           between Borrower and Purchaser of even date herewith.

                           (b) all monies due borrower as severance payments
                           pursuant to that certain Employment Agreement by and
                           between Borrower and Purchaser of even date herewith.

         It is the intention of the parties hereto that this Loan Agreement
shall constitute a security agreement under the Uniform Commercial Code and any
other applicable law and the Lender shall have the rights and remedies of a
secured party thereunder. The Borrower further agrees to deliver any financing
statement or additional document the Lender may reasonably request to perfect or
evidence the Lender's security interest granted herein.

         13. FURTHER ASSURANCES. Borrower covenants to execute such other
assignments, security agreements, financing statements, and other documents that
Lender may deem necessary to further evidence the obligations provided for
herein or to perfect, extend, or clarify Lender's rights in the Collateral.

         14. LEGAL AND BINDING AGREEMENT. Borrower warrants that the execution
and performance of this Loan Agreement will not violate any judicial or
administrative order or governmental law or regulation, and that this Loan
Agreement is valid, binding and enforceable against the Borrower in every
respect according to its terms.

         15. DEFAULT DEFINED. The occurrence of any one or more of the following
events shall constitute a default under this Loan Agreement if not cured within
ten (10) business days following receipt of written notice thereof:

                           a. Monetary Default. The failure of the Borrower to
                           timely pay to the Lender any amount due hereunder
                           following any applicable notice to Borrower as set
                           forth in the Note.

                           b. Breach of Warranty/Covenant. The failure of the
                           Borrower to materially perform or observe any
                           obligation, covenant, agreement, representation or
                           warranty contained herein.

                           c. Dissolution/Cessation of Business. The cessation
                           of the Borrower's employment with Lender, Borrower's
                           liquidation or the taking of any action by Borrower
                           to further a liquidation, including the filing by the
                           Borrower of a Chapter 7 or Chapter 13 petition under
                           the Bankruptcy Code.

                           Except as set forth herein, the Borrower waives
                           presentment, demand and protest and the right to
                           assert any statute of limitations.

<PAGE>

         16. REMEDIES UPON DEFAULT. Upon default hereunder, Lender shall give
written notice thereof to the Borrower and, if such default is not cured within
ten (10) business days of such notice, Lender may pursue any or all of the
following remedies, without any further notice to Borrower, except as required
below:

                  a. Acceleration. Lender may declare the entire amount of the
                  Loan then outstanding due and payable at once.

                  b. Recovery of Proceeds of the Collateral. Lender may recover
                  any or all proceeds of the Collateral from any bank, court or
                  other custodian who may have possession thereof. Borrower
                  hereby authorizes and directs all custodians of Borrower's
                  assets to comply with any demand for payment made by Lender
                  pursuant to this Loan agreement, without the need of prior
                  approval or confirmation from Borrower and without making any
                  inquiry as to the existence of a default hereunder or any
                  other matter. Lender may engage a collection agent to collect
                  the proceeds of the Collateral for a reasonable percentage
                  commission or on any other reasonable compensation
                  arrangement.

                  c. Enforcement of Rights of Collection. Lender may, but shall
                  not be obligated to, take such measures as Lender may deem
                  necessary in order to collect or otherwise liquidate the
                  Collateral. Without limiting the foregoing, Lender may
                  institute or continue any administrative or judicial action
                  that it may deem necessary in the course of collecting and
                  enforcing any or all of the Lender's rights in or under the
                  Collateral. Any administrative or judicial action or other
                  action taken by Lender in the course of collecting the
                  proceeds of the Collateral may be taken by Lender in its own
                  name or in Borrower's name. Lender may compromise or settle
                  any disputed claims, which compromises or settlements shall be
                  binding upon Borrower. Lender shall have no duty to pursue
                  collection of the proceeds of the Collateral, and may abandon
                  efforts to collect the proceeds of the Collateral after such
                  efforts are initiated.

                  d. Other Remedies. Lender may exercise any right that it may
                  have under any other document evidencing, securing or
                  guaranteeing the Loan or otherwise available to Lender at law
                  or equity.

                  e. Attorney-in-Fact. Borrower hereby irrevocably appoints
                  Lender as Borrower's attorney-in-fact to (i) execute
                  appropriate Form(s) UCC-1 in connection herewith and (ii)
                  attach appropriate Exhibit(s) to the Form(s) UCC-1 executed in
                  connection herewith or any other UCC forms executed in
                  connection with the transactions contemplated herein. This
                  power shall be deemed to be a power coupled with an interest
                  and is irrevocable.

                  f. Application of Proceeds. All amounts received by Lender for
                  Borrower's account by exercise of its remedies hereunder shall
                  be applied as follows: First, to the payment of all expenses
                  incurred by Lender in exercising its rights hereunder,
                  including attorney's fees, and any other expenses due Lender
                  from Borrower; Second, to the payment of all interest, if any,
                  in such order as Lender may elect; Third, to the payment of
                  all principal, in such order as Lender may elect; and, Fourth,
                  any excess to Borrower or any other party entitled thereto.

<PAGE>

         17. NO THIRD PARTY BENEFICIARIES. This Loan Agreement has been executed
for the sole benefit of Lender and its assignees, and no other third party is
authorized to rely upon Lender's rights hereunder or to rely upon an assumption
that Lender has or will exercise its rights under this Loan Agreement or under
any document referred to herein.

         19. NOTICES. Any communication concerning this Agreement shall be
addressed as follows:

         As To Lender:

                  Amedisys, Inc.
                  11100 Mead Road
                  Suite 300
                  Baton Rouge, LA 70816
                  Attention: John Joffrion

         As To Borrower:

                  John Nugent
                  3846 S. Lakeshore Dr.
                  Baton Rouge, LA 70808

         20. INDULGENCE NOT WAIVER. Lender's indulgence in the existence of a
default hereunder or any other departure from the terms of this Loan Agreement
shall not prejudice Lender's rights to declare a default or otherwise demand
strict compliance with this Loan Agreement.

         21. CUMULATIVE REMEDIES. The remedies provided Lender in this Loan
Agreement are not exclusive of any other remedies that may be available to
Lender under any other document or at law or equity.

         22. TERM; REINSTATEMENT. The security interest granted herein shall
continue until all amounts due and owing hereunder and all amounts included in
the secured indebtedness and secured hereby have been irrevocably paid in full.
If, after receipt of payment of all or any part of the Loan, Lender is for any
reason required to surrender such payment to any person because such payment is
invalidated, declared fraudulent, set aside, determined to be void or voidable
as a preference or diversion of trust funds, or for any other reason, then the
Loan or part thereof intended to be satisfied shall be revived and this Loan
Agreement and the security interest shall continue in full force as if such
payment had not been made, and Borrower shall be liable to Lender, and hereby
indemnifies Lender against and hold Lender harmless from, the amount of such
surrendered payment. These provisions shall remain effective notwithstanding any
contrary action taken by Lender in reliance on such payment which such action
shall be deemed to have been conditioned on such payment having become final an
irrevocable. The provisions of this Loan Agreement are irrevocable. Upon final
and irrevocable payment of the Loan and all amounts included in the secured
indebtedness and performance of all of Borrower's obligations hereunder, all
filings under the Uniform Commercial Code will be terminated within a reasonable
time and the provisions of this Loan Agreement shall terminate.

         23. AMENDMENT AND WAIVER IN WRITING. No provision of this Loan
Agreement can be amended or waived, except by a statement in writing signed by
all parties hereto.

<PAGE>

         24. HEADINGS. The headings and captions herein are inserted only as a
matter of convenience and for reference and in no way define, limit or describe
the scope of this Loan Agreement or the intent of any provision thereof.

         25. COUNTERPARTS. This Loan Agreement may be executed in one or more
counterparts all of which together shall constitute a binding and enforceable
agreement with respect to each party. Signatures received via facsimile shall be
binding on the parties hereto.

         26. BINDING EFFECT; ASSIGNABILITY. This Loan Agreement shall be binding
upon and inure to the benefit of the parties hereto and their respective
successors and permitted assigns. The Borrower may not assign any of his rights
and obligations hereunder or any interest herein without the prior written
consent of the Lender. The Lender may, at any time, without the consent of the
Borrower, assign any of its rights and obligations hereunder or interests herein
to any affiliate of the Lender.

         27. SEVERABILITY. The invalidity of any provision or provisions of this
Loan Agreement shall not affect the other provisions, and this Loan Agreement
shall be construed in all respects as if any invalid provisions were omitted.

         28. GOVERNING LAW. This Agreement shall governed by and construed in
accordance with the laws of the State of Louisiana.

         IN WITNESS HEREOF, this Loan Agreement has been duly executed as of the
date first above written.

AMEDISYS, INC.

By:
   -------------------------------              -------------------------------
        William F. Borne, CEO                        JOHN NUGENT, BORROWER

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00035-of-00352.parquet"}]]